MA33815B1 - Antagonistes, de type spiro-oxindole, de l'oncoprotéine mdm2 - Google Patents

Antagonistes, de type spiro-oxindole, de l'oncoprotéine mdm2

Info

Publication number
MA33815B1
MA33815B1 MA34958A MA34958A MA33815B1 MA 33815 B1 MA33815 B1 MA 33815B1 MA 34958 A MA34958 A MA 34958A MA 34958 A MA34958 A MA 34958A MA 33815 B1 MA33815 B1 MA 33815B1
Authority
MA
Morocco
Prior art keywords
antagonists
spiro
oxindole
type
compounds
Prior art date
Application number
MA34958A
Other languages
Arabic (ar)
English (en)
Inventor
Shaomeng Wang
Shanghai Yu
Wei Sun
Sanjeev Kumar
Duxin Sun
Peng Zou
Yujun Zhao
Donna Mceachern
Original Assignee
Univ Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43974649&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33815(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Michigan filed Critical Univ Michigan
Publication of MA33815B1 publication Critical patent/MA33815B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne des composés, des compositions et des procédés appartenant au domaine de la chimie médicinale. Les composés et compositions de la présente invention incluent des spiro-oxindoles qui fonctionnent comme des antagonistes de l'interaction entre la protéine p53 et l'oncoprotéine MDM2. L'invention concerne leur utilisation comme composés thérapeutiques dans le cadre du traitement du cancer et d'autres maladies.
MA34958A 2009-11-12 2012-06-11 Antagonistes, de type spiro-oxindole, de l'oncoprotéine mdm2 MA33815B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26068509P 2009-11-12 2009-11-12
US26366209P 2009-11-23 2009-11-23
PCT/US2010/056197 WO2011060049A2 (fr) 2009-11-12 2010-11-10 Antagonistes, de type spiro-oxindole, de l'oncoprotéine mdm2

Publications (1)

Publication Number Publication Date
MA33815B1 true MA33815B1 (fr) 2012-12-03

Family

ID=43974649

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34958A MA33815B1 (fr) 2009-11-12 2012-06-11 Antagonistes, de type spiro-oxindole, de l'oncoprotéine mdm2

Country Status (28)

Country Link
US (3) US8518984B2 (fr)
EP (1) EP2499145B1 (fr)
JP (1) JP2013510860A (fr)
KR (1) KR20120099462A (fr)
CN (2) CN104876938A (fr)
AR (1) AR079026A1 (fr)
AU (1) AU2010319595B2 (fr)
BR (1) BR112012011317A2 (fr)
CA (1) CA2780547C (fr)
CL (1) CL2012001250A1 (fr)
CO (1) CO6501131A2 (fr)
CR (1) CR20120313A (fr)
DO (1) DOP2012000131A (fr)
EC (1) ECSP12011943A (fr)
GT (1) GT201200147A (fr)
IL (1) IL219706A (fr)
MA (1) MA33815B1 (fr)
MX (1) MX2012005507A (fr)
NI (1) NI201200083A (fr)
NZ (1) NZ600430A (fr)
PE (1) PE20121282A1 (fr)
RU (1) RU2553269C2 (fr)
TN (1) TN2012000161A1 (fr)
TW (1) TWI508967B (fr)
UA (1) UA107814C2 (fr)
UY (1) UY33029A (fr)
WO (1) WO2011060049A2 (fr)
ZA (1) ZA201203323B (fr)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2118123T3 (en) 2007-01-31 2016-01-25 Dana Farber Cancer Inst Inc Stabilized p53 peptides and uses thereof
ES2610531T3 (es) 2007-03-28 2017-04-28 President And Fellows Of Harvard College Polipéptidos cosidos
NZ600430A (en) 2009-11-12 2014-06-27 Univ Michigan Spiro-oxindole mdm2 antagonists
US8088815B2 (en) * 2009-12-02 2012-01-03 Hoffman-La Roche Inc. Spiroindolinone pyrrolidines
SG184288A1 (en) * 2010-04-09 2012-11-29 Univ Michigan Biomarkers for mdm2 inhibitors for use in treating disease
ES2711526T3 (es) 2010-08-13 2019-05-06 Aileron Therapeutics Inc Macrociclos peptidomiméticos
NZ611866A (en) * 2010-11-12 2015-04-24 Univ Michigan Spiro-oxindole mdm2 antagonists
CN103635473B (zh) * 2011-03-10 2016-08-17 第一三共株式会社 二螺吡咯烷衍生物
JP2014513699A (ja) 2011-05-11 2014-06-05 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン スピロ−オキシインドールｍｄｍ２アンタゴニスト
RU2639523C2 (ru) 2011-10-18 2017-12-21 Эйлерон Терапьютикс, Инк. Пептидомиметические макроциклы и их применение
CA2858565A1 (fr) * 2011-12-07 2013-07-04 Duke University Procedes d'identification et d'utilisation d'inhibiteurs de mdm2
MX362492B (es) 2012-02-15 2019-01-21 Aileron Therapeutics Inc Macrociclos peptidomiméticos.
JP6450192B2 (ja) 2012-02-15 2019-01-09 エイルロン セラピューティクス，インコーポレイテッド トリアゾール架橋した、およびチオエーテル架橋したペプチドミメティック大環状化合物
TWI586668B (zh) 2012-09-06 2017-06-11 第一三共股份有限公司 二螺吡咯啶衍生物之結晶
AU2013337388B2 (en) 2012-11-01 2018-08-02 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
CA2895504A1 (fr) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Imidazopyridines substituees en tant qu'inhibiteurs de hdm2
CN103739566B (zh) * 2014-01-24 2016-01-20 中国人民解放军第三军医大学 含有磺酰胺的手性五元并环骨架化合物及制备方法和用途
SG10201913742TA (en) 2014-04-17 2020-03-30 Univ Michigan Regents Mdm2 inhibitors and therapeutic methods using the same
CN103992334A (zh) * 2014-05-29 2014-08-20 中国人民解放军第二军医大学 吲哚酮螺四氢硫代吡喃类抗肿瘤衍生物及其制备方法
JP6503386B2 (ja) 2014-07-03 2019-04-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ＭＤＭ２−ｐ５３阻害剤としての新しいスピロ［３Ｈ−インドール−３，２’−ピロリジン］−２（１Ｈ）−オン化合物および誘導体
CA2958193C (fr) * 2014-08-18 2024-02-27 Hudson Biopharma Inc. Spiropyrrolidines utiles en tant qu'inhibiteurs de mdm2
JP6412753B2 (ja) * 2014-09-19 2018-10-24 日本テルペン化学株式会社 抗菌活性を持つ化合物、およびその製造方法
JP6408318B2 (ja) * 2014-09-19 2018-10-17 日本テルペン化学株式会社 抗菌活性を持つ化合物、およびその製造方法
SG11201702175YA (en) 2014-09-24 2017-04-27 Aileron Therapeutics Inc Peptidomimetic macrocycles and formulations thereof
KR20170058424A (ko) 2014-09-24 2017-05-26 에일러론 테라퓨틱스 인코포레이티드 펩티드모방 거대고리 및 이의 용도
WO2016147205A1 (fr) * 2015-03-13 2016-09-22 Council Of Scientific & Industrial Research Nouveaux 3-spirophosphoryl pyrazole-2-oxindoles substitués en tant qu'agents anti-infectieux et procédé de synthèse correspondant
EP3294318A4 (fr) 2015-03-20 2019-04-03 Aileron Therapeutics, Inc. Macrocycles peptidomimétiques et leurs utilisations
JP2018528217A (ja) 2015-09-10 2018-09-27 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Ｍｃｌ−１のモジュレーターとしてのペプチド模倣大環状分子
US9962380B2 (en) 2015-09-23 2018-05-08 Wisconsin Alumni Research Foundation Methods for treating cognitive deficits associated with fragile X syndrome
GB201517216D0 (en) 2015-09-29 2015-11-11 Cancer Res Technology Ltd And Astex Therapeutics Ltd Pharmaceutical compounds
GB201517217D0 (en) 2015-09-29 2015-11-11 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
KR20180058832A (ko) 2015-10-09 2018-06-01 베링거 인겔하임 인터내셔날 게엠베하 Mdm2-p53 억제제로서의 스피로[3h-인돌-3,2'-피롤리딘]-2(1h)-온 화합물 및 유도체
UA123786C2 (uk) * 2016-04-06 2021-06-02 Дзе Ріджентс Оф Дзе Юніверсіті Оф Мічіган Деструктори білка mdm2
JP7001614B2 (ja) 2016-04-06 2022-02-03 ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン リガンド依存性の標的タンパク質分解のための単官能性中間体
CN109152843A (zh) 2016-05-20 2019-01-04 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法
GB201704966D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
GB201704965D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
US9822128B1 (en) 2017-06-01 2017-11-21 King Saud University Substituted spirooxindoles
CN107312115B (zh) * 2017-06-22 2020-06-12 北京理工大学 一种双吲哚稀土金属催化剂、制备方法及应用
CN109988070B (zh) * 2017-12-29 2022-07-26 南京富润凯德生物医药有限公司 反式-1-羟基-1-(三氟甲基)-3-氨基环丁烷盐酸盐的中间体及制备方法和应用
KR101857408B1 (ko) * 2018-02-28 2018-05-14 경북대학교 산학협력단 탈모 예방 또는 치료용 조성물
SG11202103282YA (en) 2018-10-08 2021-04-29 Univ Michigan Regents Small molecule mdm2 protein degraders
GB201919219D0 (en) 2019-12-23 2020-02-05 Otsuka Pharma Co Ltd Cancer biomarkers
BR112022018678A2 (pt) 2020-03-19 2022-11-01 Kymera Therapeutics Inc Degradadores de mdm2 e usos dos mesmos
CN116194088A (zh) 2020-08-27 2023-05-30 大冢制药株式会社 使用mdm2拮抗剂治疗癌症的生物标志物
US11976084B2 (en) 2020-11-23 2024-05-07 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
GB202103080D0 (en) 2021-03-04 2021-04-21 Otsuka Pharma Co Ltd Cancer biomarkers
WO2022226426A1 (fr) * 2021-04-24 2022-10-27 Universal Sequencing Technology Corporation Un nanotrain pour la détection monomoléculaire
US11970502B2 (en) 2021-05-04 2024-04-30 Enanta Pharmaceuticals, Inc. Macrocyclic antiviral agents
WO2023056069A1 (fr) 2021-09-30 2023-04-06 Angiex, Inc. Conjugués agent de dégradation-anticorps et leurs procédés d'utilisation
WO2023086352A1 (fr) 2021-11-12 2023-05-19 Enanta Pharmaceuticals, Inc. Nouveaux agents antiviraux dérivés de spiropyrrolidine
WO2023086350A1 (fr) 2021-11-12 2023-05-19 Enanta Pharmaceuticals, Inc. Agents antiviraux contenant des alcynes
US11919910B2 (en) 2021-11-12 2024-03-05 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
US11993600B2 (en) 2021-12-08 2024-05-28 Enanta Pharmaceuticals, Inc. Saturated spirocyclics as antiviral agents
WO2023177854A1 (fr) * 2022-03-18 2023-09-21 Enanta Pharmaceuticals, Inc. Procédés de préparation de dérivés de spirooxindole substitués
US11944604B1 (en) 2023-03-10 2024-04-02 King Saud University Nanoformulation of spriooxindole and methods for treating hepatocellular carcinoma

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3219661A (en) 1962-12-14 1965-11-23 Warner Lambert Pharmaceutical Spirooxindole and spirodehydroindole alkaloids and process therefor
GB1056537A (en) 1963-07-16 1967-01-25 Smith Kline French Lab Improvements in or relating to crystalline alkaloids of mitragyna citiata and compositions thereof
JPS444986Y1 (fr) 1966-10-20 1969-02-24
US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4444762A (en) 1980-04-04 1984-04-24 Nelson Research & Development Company Vehicle composition containing 1-substituted azacyclopentan-2-ones
JPH044986A (ja) 1990-04-20 1992-01-09 Nippon Stainless Steel Co Ltd ニッケル・ステンレス鋼クラッド材の製造方法
US6605712B1 (en) 1990-12-20 2003-08-12 Arch Development Corporation Gene transcription and ionizing radiation: methods and compositions
RU2084449C1 (ru) 1994-03-02 1997-07-20 Всероссийский научный центр по безопасности биологически активных веществ 1-бензил-2-оксотриптамин гидрохлорид и его производные, обладающие гепатозащитной активностью
US5773455A (en) 1996-06-28 1998-06-30 Biomeasure, Incorporated Inhibitors of prenyl transferases
US7083983B2 (en) 1996-07-05 2006-08-01 Cancer Research Campaign Technology Limited Inhibitors of the interaction between P53 and MDM2
WO1998031378A1 (fr) 1997-01-20 1998-07-23 Immodal Pharmaka Gesellschaft Mbh Procede et substances pour liberer un facteur de croissance issu des cellules endotheliales, facteur de croissance libere selon ce procede, et son utilisation
CA2302650A1 (fr) 1997-09-08 1999-03-18 William J. Ryan Composes de spiro¬pyrrolidine-2,3'-oxindole| et procedes d'utilisation
EP1109020B1 (fr) 1998-08-20 2008-12-24 Chugai Seiyaku Kabushiki Kaisha Procede de criblage de composes d'interet potentiel destines a un medicament antitumoral
US7205404B1 (en) 1999-03-05 2007-04-17 Metabasis Therapeutics, Inc. Phosphorus-containing prodrugs
US6831155B2 (en) 1999-12-08 2004-12-14 President And Fellows Of Harvard College Inhibition of p53 degradation
CN1182083C (zh) 2001-10-08 2004-12-29 廖宜芳 一种杀虫灭菌的配位肥及其制造方法
CA2468783A1 (fr) 2001-12-18 2003-06-26 F. Hoffmann-La Roche Ag Cis-imidazolines inhibiteurs de mdm2
WO2003051359A1 (fr) 2001-12-18 2003-06-26 F.Hoffmann-La Roche Ag Cis-2,4,5- triphenyl-imidazolines et leurs utilisations dans le traitement des tumeurs
JP4023184B2 (ja) 2002-03-11 2007-12-19 昭和電工株式会社 発光体粒子及びその製造方法並びにその用途
US7514579B2 (en) 2002-06-13 2009-04-07 Johns Hopkins University Boronic chalcone derivatives and uses thereof
US20040171035A1 (en) 2002-11-08 2004-09-02 Irm Llc Methods and compositions for modulating P53 transcription factor
US20050227932A1 (en) 2002-11-13 2005-10-13 Tianbao Lu Combinational therapy involving a small molecule inhibitor of the MDM2: p53 interaction
CA2514374A1 (fr) 2003-02-13 2004-09-02 Government Of The United States Of America, As Represented By The Secret Ary, Department Of Health And Human Services Composes de deazaflavine et leurs methodes d'utilisation
US6916833B2 (en) 2003-03-13 2005-07-12 Hoffmann-La Roche Inc. Substituted piperidines
US7132421B2 (en) 2003-06-17 2006-11-07 Hoffmann-La Roche Inc. CIS-imidazoles
US7425638B2 (en) 2003-06-17 2008-09-16 Hoffmann-La Roche Inc. Cis-imidazolines
US7589233B2 (en) 2003-07-29 2009-09-15 Signature R&D Holdings, Llc L-Threonine derivatives of high therapeutic index
US8173840B2 (en) 2003-07-29 2012-05-08 Signature R&D Holdings, Llc Compounds with high therapeutic index
NZ601772A (en) 2003-07-29 2012-10-26 Signature R & D Holdings Llc Amino Acid Prodrugs
US7829742B2 (en) 2003-12-22 2010-11-09 Johns Hopkins University Boronic acid aryl analogs
US8598127B2 (en) 2004-04-06 2013-12-03 Korea Research Institute Of Bioscience & Biotechnology Peptides for inhibiting MDM2 function
TWI350168B (en) 2004-05-07 2011-10-11 Incyte Corp Amido compounds and their use as pharmaceuticals
BRPI0511328A (pt) 2004-05-18 2007-12-04 Hoffmann La Roche cis-imidazolinas
GB0419481D0 (en) 2004-09-02 2004-10-06 Cancer Rec Tech Ltd Isoindolin-1-one derivatives
NZ553646A (en) 2004-09-22 2010-07-30 Janssen Pharmaceutica Nv Inhibitors of the interaction between MDM2 and p53
CN101160314B (zh) * 2005-02-22 2012-05-23 密执安州立大学董事会 Mdm2的小分子抑制剂以及其应用
NZ561215A (en) 2005-02-22 2010-12-24 Univ Michigan Small molecule inhibitors of MDM2 and uses thereof
KR101333861B1 (ko) 2005-05-24 2013-11-28 메르크 세로노 에스. 에이. Ｃｒｔｈ２ 조정자로서 삼환계 스피로 유도체
US7576082B2 (en) * 2005-06-24 2009-08-18 Hoffman-La Roche Inc. Oxindole derivatives
ES2350504T3 (es) * 2006-03-13 2011-01-24 F. Hoffmann-La Roche Ag Derivados de espiroindolinona.
US7495007B2 (en) 2006-03-13 2009-02-24 Hoffmann-La Roche Inc. Spiroindolinone derivatives
CA2644643C (fr) 2006-03-22 2015-05-19 Janssen Pharmaceutica N.V. Inhibiteurs de l'interaction entre mdm2 et p53
US7737174B2 (en) 2006-08-30 2010-06-15 The Regents Of The University Of Michigan Indole inhibitors of MDM2 and the uses thereof
CA2661354C (fr) 2006-08-30 2012-12-18 The Regents Of The University Of Michigan Nouvelles petites molecules inhibitrices de mdm2 et leurs utilisations
US8222288B2 (en) 2006-08-30 2012-07-17 The Regents Of The University Of Michigan Small molecule inhibitors of MDM2 and the uses thereof
US8002528B2 (en) * 2006-09-18 2011-08-23 Emerson Climate Technologies, Inc. Compressor assembly having vibration attenuating structure
CA2662838A1 (fr) 2006-09-21 2008-03-27 F. Hoffmann-La Roche Ag Derives d'oxindole
US7638548B2 (en) 2006-11-09 2009-12-29 Hoffmann-La Roche Inc. Spiroindolinone derivatives
WO2008072655A1 (fr) 2006-12-14 2008-06-19 Daiichi Sankyo Company, Limited Dérivés d'imidazothiazole
WO2008106507A2 (fr) 2007-02-27 2008-09-04 University Of South Florida Peptide inhibiteur de mdm2/mdmx
WO2008119741A2 (fr) 2007-03-29 2008-10-09 Novartis Ag 3-imidazolyl-indoles pour le traitement de maladies prolifératives
US7625895B2 (en) 2007-04-12 2009-12-01 Hoffmann-Le Roche Inc. Diphenyl-dihydro-imidazopyridinones
WO2008130614A2 (fr) 2007-04-20 2008-10-30 University Of Pittsburg-Of The Commonwealth System Of Higher Education Antagonistes p53/mdm2/mdm4 sélectifs et à action double
US7553833B2 (en) 2007-05-17 2009-06-30 Hoffmann-La Roche Inc. 3,3-spiroindolinone derivatives
US7834179B2 (en) 2007-05-23 2010-11-16 Hoffmann-La Roche Inc. Spiroindolinone derivatives
US8288377B2 (en) 2007-09-21 2012-10-16 Janssen Pharmaceutica N.V. Inhibitors of the interaction between MDM2 and p53
RU2360914C1 (ru) * 2007-10-31 2009-07-10 Государственное образовательное учреждение высшего профессионального образования "Пермский государственный университет" Анальгетическое средство
CZ301561B6 (cs) 2007-12-04 2010-04-14 Výzkumný ústav živocišné výroby, v. v. i. Prostredek pro prevenci a potlacování kokcidióz
US8134001B2 (en) 2007-12-14 2012-03-13 Hoffmann-La Roche Inc. Spiroindolinone derivatives
US7776875B2 (en) 2007-12-19 2010-08-17 Hoffman-La Roche Inc. Spiroindolinone derivatives
US7723372B2 (en) 2008-03-19 2010-05-25 Hoffman-La Roche Inc. Spiroindolinone derivatives
EP2298778A4 (fr) 2008-06-12 2011-10-05 Daiichi Sankyo Co Ltd Dérivé d imidazothiazole ayant une structure cyclique de 4,7-diazaspiroý2.5¨octane
GB0811643D0 (en) 2008-06-25 2008-07-30 Cancer Rec Tech Ltd New therapeutic agents
US7928233B2 (en) 2009-02-10 2011-04-19 Hoffmann-La Roche Inc. Spiroindolinone pyridine derivatives
US8076482B2 (en) 2009-04-23 2011-12-13 Hoffmann-La Roche Inc. 3,3′-spiroindolinone derivatives
NZ600430A (en) * 2009-11-12 2014-06-27 Univ Michigan Spiro-oxindole mdm2 antagonists
US8088815B2 (en) 2009-12-02 2012-01-03 Hoffman-La Roche Inc. Spiroindolinone pyrrolidines
US8288431B2 (en) 2010-02-17 2012-10-16 Hoffmann-La Roche Inc. Substituted spiroindolinones
WO2011106650A2 (fr) 2010-02-27 2011-09-01 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Nouveaux antagonistes de p53-mdm2/p53-mdm4 pour traiter une maladie de prolifération
SG184288A1 (en) * 2010-04-09 2012-11-29 Univ Michigan Biomarkers for mdm2 inhibitors for use in treating disease
US8217044B2 (en) 2010-04-28 2012-07-10 Hoffmann-La Roche Inc. Spiroindolinone pyrrolidines
US20120046306A1 (en) 2010-08-18 2012-02-23 David Joseph Bartkovitz Substituted Heteroaryl Spiropyrrolidine MDM2 Antagonists
US20120071499A1 (en) 2010-09-20 2012-03-22 Xin-Jie Chu Substituted Spiro[3H-Indole-3,6'(5'H)-[1H]Pyrrolo[1,2c]Imidazole-1',2(1H,2'H)-diones
NZ611866A (en) * 2010-11-12 2015-04-24 Univ Michigan Spiro-oxindole mdm2 antagonists
JP2014513699A (ja) 2011-05-11 2014-06-05 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン スピロ−オキシインドールｍｄｍ２アンタゴニスト

Also Published As

Publication number Publication date
TWI508967B (zh) 2015-11-21
CR20120313A (es) 2012-07-24
PE20121282A1 (es) 2012-10-12
UY33029A (es) 2011-06-30
CN102712650B (zh) 2015-05-20
CL2012001250A1 (es) 2012-11-30
AR079026A1 (es) 2011-12-21
UA107814C2 (uk) 2015-02-25
EP2499145A4 (fr) 2013-07-10
BR112012011317A2 (pt) 2019-09-24
CA2780547A1 (fr) 2011-05-19
AU2010319595A1 (en) 2012-06-28
EP2499145A2 (fr) 2012-09-19
EP2499145B1 (fr) 2016-01-27
US8877796B2 (en) 2014-11-04
KR20120099462A (ko) 2012-09-10
GT201200147A (es) 2014-08-26
IL219706A (en) 2016-07-31
JP2013510860A (ja) 2013-03-28
RU2012124056A (ru) 2013-12-20
US20110112052A1 (en) 2011-05-12
NI201200083A (es) 2012-10-29
RU2553269C2 (ru) 2015-06-10
CO6501131A2 (es) 2012-08-15
CA2780547C (fr) 2015-02-03
IL219706A0 (en) 2012-07-31
CN102712650A (zh) 2012-10-03
ECSP12011943A (es) 2012-07-31
US9079913B2 (en) 2015-07-14
DOP2012000131A (es) 2012-09-30
NZ600430A (en) 2014-06-27
ZA201203323B (en) 2013-01-30
MX2012005507A (es) 2012-07-03
WO2011060049A3 (fr) 2011-10-20
WO2011060049A2 (fr) 2011-05-19
TN2012000161A1 (en) 2013-12-12
US20130296303A1 (en) 2013-11-07
AU2010319595B2 (en) 2015-09-17
US8518984B2 (en) 2013-08-27
CN104876938A (zh) 2015-09-02
US20140378680A1 (en) 2014-12-25
TW201129570A (en) 2011-09-01

Similar Documents

Publication Publication Date Title
MA33815B1 (fr) Antagonistes, de type spiro-oxindole, de l'oncoprotéine mdm2
MA34732B1 (fr) Spiro-oxindoles antagonistes de mdm2
MA34780B1 (fr) Anticorps se liant de façon préférentielle au domaine extracellulaire 4 de csf1r human et leur utilisation
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
MA37794A1 (fr) Anticorps bispécifiques anti-vegf/anti-ang-2 et leur utilisation dans le cadre du traitement de pathologies vasculaires oculaires
TN2010000068A1 (en) Anticorps anti-cd37
EA201300246A1 (ru) Ингибиторы тирозинкиназы брутона
MEP53308A (en) Novel peptides that bind to the erythropoietin receptor
MA34763B1 (fr) Anticorps anti-cd38
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
EA201500393A1 (ru) Ингибиторы тирозинкиназы брутона
EA200901133A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
MA32729B1 (fr) Derives d'acide 1-amino-2-cyclobutylethylboronique
MA38183A1 (fr) Composés pyrrolopyrimidines en tant qu'inhibiteurs de kinase
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201001680A1 (ru) Соединения бензолсульфонамидтиазола и оксазола
EA201170036A1 (ru) Соединения боронатного эфира и его фармацевтические составы
EA200800952A1 (ru) Конъюгаты антитело-лекарство и способы применения
EA201170624A1 (ru) Изоникотинамидные антагонисты рецепторов орексинов
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
MX2009007337A (es) Indazoles sustituidos con 5-piridinona.
EA200602242A1 (ru) 3-аминоциклопентанкарбоксамиды в качестве модуляторов хемокиновых рецепторов
MA27880A1 (fr) Derives de tetrahydrocarbazole et leur utilisation pharmaceutique
EA200801343A1 (ru) Иммуноглобулины, направленные против nogo
MA38190A2 (fr) Inhibiteurs d'autotaxine